Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Christoph Pöttgen, Godehard Friedel, Stefanie Veit, Vanessa Heinrich, Stefan Welter, Werner Spengler, Martin Kimmich, Berthold Fischer, Heinz Schmidberger, Eleni Gkika, Sebastian Cordes, Rodrigo Hepp, Diana Luetke-Brintrup, Nils Lehmann, Martin H. Schuler, Karl-Heinz Jöckel, Georgios Stamatis, Martin Stuschke
Institutions: Ruhrlandklinik, Essen University Hospital, University of Duisburg-Essen, Stiftung Universitätsmedizin Essen, Robert Bosch Hospital, Klinik Schillerhöhe, Universitätsklinikum Tübingen, University of Tübingen, University Medical Center of the Johannes Gutenberg University Mainz, Johannes Gutenberg University Mainz, Institut für Medizinische Informatik, Biometrie und Epidemiologie
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2602831972